Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879932 | 0.85 | SIGMAR1 (0.44) | KMT2ASIGMAR1ALDH1A1MMP1MMP2 | |
| SCHEMBL4880460 | 0.84 | ELOVL1 (0.43) | KMT2ASIGMAR1ALDH1A1ELOVL1MEN1 | |
| SCHEMBL4876705 | 0.82 | OPRD1 (0.46) | KMT2AALDH1A1ELOVL1MEN1OPRD1 | |
| SCHEMBL4880129 | 0.82 | SIGMAR1 (0.41) | KMT2ASIGMAR1ALDH1A1MIFMAOB | |
| SCHEMBL4880538 | 0.79 | SOAT1 (0.50) | KMT2AALDH1A1MMP2MMP9MEN1 | |
| SCHEMBL4877598 | 0.79 | OPRD1 (0.41) | KMT2AALDH1A1ELOVL1MEN1OPRD1 | |
| SCHEMBL4880349 | 0.79 | HDAC4 (0.46) | KMT2AALDH1A1ELOVL1MEN1OPRD1 | |
| SCHEMBL4878256 | 0.78 | ALDH1A1 (0.43) | KMT2AALDH1A1ELOVL1MEN1 | |
| SCHEMBL4877673 | 0.78 | KMT2A (0.42) | KMT2AALDH1A1MMP1MMP2MEN1 | |
| SCHEMBL4883883 | 0.77 | MMP1 (0.52) | SIGMAR1ALDH1A1MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | KMT2A 1132/4885SIGMAR1 298/4885ALDH1A1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.